Breaking Finance News

Zacks Investment Research announced Avinger Inc (NASDAQ:AVGR), bumping up its stock price target to $0.50 today

In a statement issued on 06/20/2017 Zacks Investment Research bumped up the target of Avinger Inc (NASDAQ:AVGR) to $0.50 stating a possible upside of 0.04%.

Yesterday Avinger Inc (NASDAQ:AVGR) traded -4.77% lower at $0.48. The company’s 50-day moving average is $0.27 and its 200-day moving average is $1.36. The last stock close price is down -82.96% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 1,176,241 shares of the stock were exchanged, up from an average trading volume of 783,580

See Chart Below

Avinger Inc (NASDAQ:AVGR)

Avinger Inc has a 52 week low of $0.22 and a 52 week high of $5.15 The company’s market cap is currently $0.

About Avinger Inc (NASDAQ:AVGR)

Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company's products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.